Reply

Since July 2016, Drs Relhan et al have either individually or collectively written 2 editorials and 3 letters in this journal opposing the practice of routine intracameral antibiotic prophylaxis (ICAP) for cataract surgery. We agree that ICAP remains controversial because of the paucity of level 1 evidence. Javitt's oft-cited editorial elegantly summarizes the multiple reasons that a prospective, randomized, placebo-controlled trial is so difficult, expensive, impractical, and potentially unethical to now perform.
Source: Ophthalmology - Category: Opthalmology Authors: Tags: Correspondence Source Type: research